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ABSTRACT
Recent developments in G protein-coupled recep-
tor (GPCR) structural biology and pharmacology
have greatly enhanced our knowledge of receptor
structure-function relations, and have helped im-
prove the scientific foundation for drug design stud-
ies. The GPCR database, GPCRdb, serves a dual role
in disseminating and enabling new scientific devel-
opments by providing reference data, analysis tools
and interactive diagrams. This paper highlights new
features in the fifth major GPCRdb release: (i) GPCR
crystal structure browsing, superposition and dis-
play of ligand interactions; (ii) direct deposition by
users of point mutations and their effects on ligand
binding; (iii) refined snake and helix box residue dia-
gram looks; and (iii) phylogenetic trees with receptor
classification colour schemes. Under the hood, the
entire GPCRdb front- and back-ends have been re-
coded within one infrastructure, ensuring a smooth
browsing experience and development. GPCRdb is
available at http://www.gpcrdb.org/ and it’s open
source code at https://bitbucket.org/gpcr/protwis.
INTRODUCTION
Gprotein-coupled receptors (GPCRs) constitute the largest
family of membrane proteins with approximately 800 mem-
bers in human (1). Roughly half are sensory mediating ol-
faction, vision, taste and pheromone recognition (2). Of
the non-sensory receptors, two-thirds regulate a plethora of
physiological processes ranging nervous and endocrine sys-
tems, whereas the remaining (∼120 receptors) are still or-
phan receptors with unknown endogenous ligand and/or
function (IUPHAR/BPS Guide to PHARMACOLOGY
database, GtoPdb). GPCRs have been systematized based
on sequence homology into the classes A–F (3) or the
GRAFS families (acronym based on the prototypical mem-
bers) (4). These are further subdivided into receptor fami-
lies based on their endogenous ligands that span ions, neu-
rotransmitters, lipids, carbohydrates, nucleotides, amino
acids, peptides and proteins (5).
GPCRs constitute the targets of more than a quarter
of all FDA approved drugs (6), but the majority, includ-
ing 58% of the Class A receptors, are still unexploited
in therapies/trials (7). A considerate number of receptors,
both orphan and liganded, are still actively being pursued
to characterize receptor functions/networks and to estab-
lish target disease validation. Thanks to a deeper insight
into pharmacological mechanisms; such as polypharma-
cology, allosteric modulation of the physiological activity
and ligand-dependent biased signalling through specific sig-
nalling protein profiles; there are now alternative concepts
to attempt a favourable therapeutic response (8). Further-
more, the recent flurry of X-ray activities hasmade available
a large number of templates forGPCR structure-based drug
design.
Crystal structures are now available for all of the hu-
man GPCR classes. These have revealed mechanisms of or-
thosteric and allosteric (9) ligand binding, conformational
changes upon receptor activation (10–12), and the modes
of binding of G protein (13,14) and -arrestin (15) signal
mediators. The transmembrane domain of GPCRs consists
of seven helices forming the signal transduction machinery.
This domain also comprises the orthosteric binding site of
Class A and B1 (Secretin family) receptor ligands, whereas
it acts as an allosteric site for modulation of Class B2 (Ad-
hesion family), C and F GPCRs (16) that bind their natural
ligands within their extracellular N-terminus. On the intra-
cellular side, the helical bundle, loops and C-terminus bind
G proteins and/or -arrestin (8).
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The GPCR database, GPCRdb was started in 1993 by
Gert Vriend, Ad IJzerman, Robert Bywater and Friedrich
Rippmann. Over two decades, GPCRdb evolved to be a
comprehensive information system, storing and analysing
GPCR data (17–20). In 2013, the stewardship of GPCRdb
was transferred to the David Gloriam group at the Univer-
sity of Copenhagen, backed up by an international team
from the EU COST Action ‘GLISTEN’ (21). The latest
release of GPCRdb offers access to a variety of updated
and new experimentally derived data: (i) All GPCR crystal
structures in the PDB, as well as 309 ligand fragments from
crystal structures that may be used to build new pharma-
cophores or even de novo ligands; (ii) The largest collection
of GPCR single-point mutations, which may now be de-
posited directly by users and include observed effects on lig-
and activities; and (iii) Reference sequence alignments that
build on structural annotation ensuring that the residues
aligned in sequence are those that reside at the correspond-
ing structure position. Furthermore, GPCRdb features a
powerful yet simple-to-use suite of analysis tools and visual-
ization diagrams. Below, these are all described as provided
in the menu system for: GPCRdb, Receptors, Sequences,
Structures, Mutations, Sites, Residue numbers and Links.
GPCRDB INFRASTRUCTURE IMPROVEMENTS
Consolidation under Python and Django, and open source re-
lease
TheGPCRdb infrastructure has been re-coded, and consol-
idated into an integrated system written in Python (v3.4),
using the Django Framework (v1.8) and the PostgreSQL
database management system (v9.3). This allows for a re-
sponsive plug-in-independent web browser experience, and
for the web interface to access the same core functionality as
the back-end, which is advantageous for day-to-day main-
tenance, as well as for new developments. The complete
GPCRdb source code is freely available at https://bitbucket.
org/gpcr/protwis under the Apache 2.0 license.
Virtual machine
GPCRdb provides a virtualmachine for running a local ver-
sion of the resource. This is ideal for developers interested
in building on top of GPCRdb functionality, or contribut-
ing to the project. The virtual machine can also be used to
maintain a local version, e.g. to combine the GPCRdb data
with proprietary data or where IT policies prohibits the use
of external databases. Instructions for setting up the virtual
machine on Linux, Mac and Windows are freely available
at https://bitbucket.org/gpcr/protwis vagrant.
Web services
GPCRdb now offers REST web services to enable pro-
grammatic access to receptor, family, mutation and struc-
ture data, as well as sequence alignments and diagrams. The
services allow access to data through the Hypertext Trans-
fer Protocol (HTTP) and serve a response in Javascript Ob-
ject Notation (JSON) format. The services were built us-
ing Django REST Framework (v3.1). Examples of how to
access the data using Python are provided at http://docs.
gpcrdb.org/web services.html.
RECEPTORS
The Receptors menu gives direct access to all data for
one receptor or receptor family, in contrast to other menu
items that represent one data type across multiple receptors.
GPCRdb contains all human GPCRs, except the olfactory
receptors and all species orthologues in TrEMBL (22). The
receptor nomenclature follows that of NC-IUPHAR (23),
also listing the gene and alternative protein names from
Uniprot. Receptors are hierarchically organized by class,
endogenous ligand type, receptor family and subtype; e.g.
Class A––peptide receptors––Angiotensin receptors––AT1
receptor. The receptor families can be browsed and analysed
in the same way as the individual receptors throughout the
database. It is, for example, possible to depict their common
mutation data, and to use their consensus sequences to gen-
erate sequence alignments and phylogenetic trees.
Residue diagrams – snake and helix box diagrams
The snake and helix box diagrams visualize receptor residue
topologies as seen from the side and above of the cell mem-
brane, respectively (Figure 1A–B). Snake-like diagrams now
include full termini, loops, as well as helix 8. The helix box
diagrams are designed to best represent the 3D receptor
structure, for example helices have four sides because a heli-
cal turn contains approximately four residues. Furthermore,
helix bulges or constrictions (observed in structures) can
offset structural and sequence alignments (24), but are cor-
rected for by single amino acid insertion and removal, re-
spectively. Residue numbers can be displayed by hovering
the cursor. Amino acids can be coloured to illustrate residue
physico-chemical properties, mutation data presence ormu-
tation effects on ligand binding or potencies, where avail-
able. The diagrams can be downloaded as a picture file or
in scalable vector graphics format for further editing.
STRUCTURES
Structure data
Hitherto, 132 GPCR structures have been reported for 30
unique receptor subtypes. Although wonderful to have, all
these data pose challenges in keeping track of what is avail-
able, and what is the most relevant receptor (ligand com-
plex) for a given study. The Structure statistics page features
bar diagrams that depict the number of unique or total crys-
tallized GPCRs in the protein data bank (PDB) (25) split
by ligand type or year (Figure 2), and phylogenetic trees
(Figure 3) that show the coverage within each GPCR Class.
The Structure browser allows for the selection of GPCR
structures based on human annotations of receptor classes,
crystallized and endogenous ligands, auxiliary proteins and
structure properties, such as resolution.
Structure tools
The structural tools are available both as separate tools
and via the Structure browser. They process user-uploaded
(model) and browsed (crystal) structures, respectively. The
PDB file residue numbering tool assigns generic numbers to
PDB files (see below). The Superposition tool allows users
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Figure 1. (A) Snake and (B) helix box diagrams show the receptor residue topologies as seen from the side and top, respectively. In the latest installment
of the GPCRdb, the diagrams are used to visualize physico-chemical properties, mutation (fold) effects on ligand binding, and ligand interactions from
crystal structure complexes. This example depicts the consensus sequence of the human metabotropic glutamate receptors with colour coding of mutation
effects on ligand binding. Colour scheme; Increased binding/potency: >5-fold (light green), >10-fold (dark green); Reduced binding/potency: >5-fold
(light red), >10-fold (dark red); <5-fold/no effect (yellow); and unknown effect (gray).
Figure 2. The bar diagrams in the Structure statistics page plot the number of unique or total crystallized GPCRs in the protein data bank (PDB) (25) by
year and the colours indicate the type of ligand.
to superpose GPCR structures based on the overall or any
substructure, e.g. ligand binding residues, and download
in PDB format. The Download tool also supports over-
all or custom substructures. Finally, the Template selection
tool for homology modelling extends the crystal structure
browser with sequence similarities for a user-defined target.
SEQUENCES
Structure-based sequence alignments
GPCRdb features alignments of all human GPCR classes
A–C and F (D and E are non-human), covering all non-
olfactory human receptors (398) and species orthologues in
Swiss-Prot andTrEMBL (>18 000). Traditionally, sequence
alignments have been based solely on conserved sequence
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Figure 3. This figure shows the human Class B1 (Secretin family) GPCRs. Custom Phylogenetic trees can swiftly be calculated under the Sequences tools
menu. The interpretation of the trees is guided by coloured bars next to the receptor names that list the GPCR class, ligand type and receptor family,
respectively. Receptors that have been crystallized can be highlighted with a blue background, and other background colours can be manually assigned
to produce custom illustrations. Pre-generated phylogenetic trees available in the Structure statistics page show the structural coverage within each GPCR
Class. For Class A, the consensus sequences are used for receptor families without a structure, whereas all receptor subtypes are included for the other
Classes.
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motifs, and where available, supporting mutagenesis data.
This is problematic as some transmembrane helices and/or
receptors lack such conservedmotifs, especially between the
GPCR classes. Furthermore, the seven transmembrane he-
lices frequently contain irregularities, i.e. bulges or constric-
tions, introducing insertions and gaps, respectively, as com-
pared to a normal helix followed by an alignment offset
(24). GPCRdb has capitalized on this wealth of structure
information and replaced the traditional sequence-based
alignments with structure-based alignments that are better
for many applications including inference of mutation ef-
fects, comparison of binding sites and homology modelling
(26). Such alignments ensure residue correspondences by
aligning the same residues in sequence as aligned in super-
position of GPCR crystal structures, as described hereun-
der.
First, a manual annotation takes place by superposi-
tion of representative (inactive) structures for crystallized
GPCRs. This annotation defines (i) the location of the
generic numbering reference position (X.50) within the re-
ceptor protein sequence, (ii) the ends of structural con-
servation for compared segments; transmembrane helices
and helix 8; and (iii) any transmembrane helix bulges or
constrictions. On this basis, a reference crystal structure-
based sequence alignment is built in which residues are
only aligned in sequence if they reside in the equivalent
structural position. Subsequently, non-crystallized recep-
tors are appended to the alignment by assigning them the
same structural information as theirmost homologous crys-
tal structure – this is the same principle as in homology
modelling. Finally, a correction is made in cases where a
specific sequence motif has been found to induce a certain
bulge or constriction configuration. Thus, retrieval of any
GPCRdb alignment represents the look-up of a subset from
this overall all-receptor alignment. Below each alignment,
three forms of residue conservation statistics are presented:
(i) a consensus sequence, (ii) the prevalence of the 20 amino
acids, and (iii) shared properties, such as aromaticity, charge
or hydrogen bonding ability.
Sequence tools
Sequence similarity is often used to deduct homology and
to infer shared physiological functions. GPCRdb includes
BLAST similarity search (27) to quickly find the most sim-
ilar sequences for a user-provided query. The GPCRdb
similarity search also makes query-to-database searches,
but uses the reference structure-based alignments for both
queries and hit sequences, and is able to restrict the search to
specific segments – custom sets of transmembrane helices or
residues (by generic numbers). Hits are aligned in order of
sequence identity, similarity or alignment score; and can be
downloaded as either an alignment file (fasta) or a spread-
sheet (csv).
All-to-all receptor comparisons of sequence identities
and similarities can be displayed in a similarity matrix. Phy-
logenetic trees (28) can be generated with up to 100 boot-
straps based on any GPCR 7TM subsequence. They can be
displayed in circular and ladder representations, and down-
loaded as figures or in Newick format for use in tree view-
ing software. The interpretation of the trees is guided by
coloured bars next to the receptor names that list theGPCR
class, ligand type and receptor family, respectively (Figure
3). Furthermore, receptors that have been crystallized can
be highlighted with a blue background, and other back-
ground colours can be manually assigned to produce cus-
tom illustrations.
MUTATIONS
Literature contains vast amounts of mutagenesis studies
pinpointing receptor residues involved in ligand binding
and efficacy. GPCRdb holds a large collection of manually
annotated such mutations, currently over 12 000 mutations
for 192 receptors (21,29). Previously, only the minimal in-
formation has been stored: the receptor, residue number,
wild type and mutation amino acids and a reference pub-
lication. In the last year, the annotation was extended with
the effect on ligand affinity or potency, and receptor surface
expression or basal activity. We added 1536 new mutations,
including all publishedClass CGPCRmutations residing in
the transmembrane domain.Users can now themselves sub-
mit mutations to generate illustrations for publication (be-
low) or to increase the dissemination of already published
studies. To ensure that data from different sources are uni-
form, the deposition uses an excel file in which data are de-
scribed using controlled vocabularies and identifiers from
public databases.
The Mutation browser allows for browsing and down-
load of mutations for specific receptors and their subdo-
mains. The Residue diagrams, snake-plots and helix box di-
agrams (Figure 1), can be custom-coloured or coloured au-
tomatically to highlight the effects of mutations on ligand
binding or potency. Residue tables show the same colour
coding as the diagrams and allow for the comparison ofmu-
tations across receptor families and subtypes (Figure 4).
SITES
Ligand interactions
Ligand binding sites have been annotated for all GPCR-
ligand complexes in the PDB, and can be automatically gen-
erated for a user-uploaded pdb file, e.g. from ligand docking
in a receptor model. The predefined binding sites can be ac-
cessed on per structure basis, and currently cover 1201 lig-
and interactions from 107 complexes of 29 receptors with 65
ligands. The receptor–ligand interactions can be visualized
in a rotatable 3D structure viewer and schematic 2D interac-
tion diagram implemented with 3dmol.js (http://3dmol.csb.
pitt.edu) and PoseView (30), respectively (Figure 5). Fur-
thermore, as for the mutations, ligand interactions can also
be visualized in Residue diagrams, helix box and snake di-
agrams (Figure 1), and compared in Residue tables (Figure
4) across receptor families and subtypes.
Site tools
The Site search tool matches a sequence/structure site, such
as a ligand binding site or structural motif, against the
GPCRdb reference alignments to retrieve a set of match-
ing receptor (off-) target profiles. This is relevant to ra-
tionalize observed polypharmacology, select receptor pan-
els for off-target screening, or ligand inference from old to
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Figure 4. Residue Tables give a side-by-side comparison of subtype residues lined up by their common generic residue number. Like the Residue Diagrams
(Figure 1), they can be colour coded to visualize physico-chemical properties, mutation (fold) effects on ligand binding and ligand interactions from
crystal structure complexes. This Residue Table depicts the human metabotropic glutamate receptor mutations in the transmembrane helices 1–2 coloured
according to their effects on ligand binding (see Figure 1).
Figure 5. Receptor–ligand interactions from structure complexes (pdb file upload) can be visualized either in (A) a rotatable 3D structure viewer or (B) a
schematic 2D interaction diagram.
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new targets. The site search tools differs from the above se-
quence similarity tools in that it discriminates receptors into
matches and non-matches, and that each residue position is
assigned a specific set of allowed amino acids, specifically
only those that have the desired functional property such as
hydrophobicity, hydrogen bond donor capability and size.
This GPCRdb update has made this tool significantly more
accessible by simplifying the manual site definition, and
adding an automatic definition of ligand binding sites by
upload of a receptor–ligand pdb file.
The Pharmacophore generation tool for GPCR binding
sites (31) is based on the inference of crystal structure frag-
ments between homologous receptors, and does therefore
not require known ligands or receptor structures for the tar-
get of interest. A pharmacophore fragment is the pair of one
ligandmoiety interacting with one receptor residue. The an-
notated fragment library has in total 309 such fragments
that cover 29 residue positionswithin the generic transmem-
brane binding pocket (32). Users can automatically select a
crystal structure template, match and superpose fragments
(all or representative) to download a single zip file contain-
ing the receptor structure and all superposedmatching frag-
ments in pdb format.
RESIDUE NUMBERS
A generic residue number gives an index of a transmem-
brane helix residue position within a multiple sequence
or structure alignment. GPCRdb provides all the estab-
lished sequence-based residue numbering schemes for the
Classes A: Ballesteros andWeinstein (33), B: Wootten et al.
(34), C: Pin et al. (35) and F: Wang et al. (36). Recently,
GPCRdb also introduced a structure-based GPCRdb num-
bering, which is the same as the above but corrects for struc-
tural distortions, helical bulges and constrictions, to ensure
that the residues aligned in sequence are those that align
in structure (24). In GPCRdb, residue numbers can be re-
trieved directly in the Structure-based sequence alignments
or within Residue tables (Figure 4). The PDB file residue
numbering tool assigns numbers to any user-provided struc-
ture (Figure 6).
LINKS
GPCRdb is cross-referenced to the IUPHAR/BPS
GuideToPharmacology (GToPdb) (5), UniProt (22) and
BitterDb (37) databases. GPCRdb has adopted the official
NC-IUPHAR receptor names, and have made available to
NC-IUPHAR the receptor residue diagrams and muta-
tions for direct access in GToPdb. GPCRdb and GToPdb
contain complementary receptor structure/sequence, and
ligand/pharmacological data, respectively, and the release
of harmonized web services will allow users to combine
data from the two resources. Furthermore, GPCRdb
contains links to several specialized GPCR servers for
homology modelling: GPCRM (38), GoMoDo (39) and
SSFE (40); andmolecular dynamics: GPCRMod-Sim (41).
Our developers continuously exchange information, e.g. at
the biannual GPCRdb satellites at the GLISTEN EU Cost
meetings, and the GPCRdb web services may be used by
partners to retrieve reference data, such as the structure-
Figure 6. Display of generic residue numbers inserted into a pdb file and
visualized with the Maestro labelling plugin. This example shows the
sequence-based Ballesteros–Weinstein numbers, and where these are off-
set by helix distortions, the structure-basedGPCRdb residue numbers (24)
within the crystal structure of 2-adrenergic receptor (pdb: 2RH1).
based sequence alignments. For information on how to
link to GPCRdb, visit http://docs.gpcrdb.org/linking.html.
CONCLUSIONS AND FUTURE PERSPECTIVES
In conclusion, the fifth release of GPCRdb offers experi-
mental and derived data, visualization diagrams and anal-
ysis tools for the wider GPCR community. The move to
one integrated system makes the user-interface more re-
sponsive and facilitates the development. The manual data
annotation encompasses on GPCR crystal structures, se-
quence alignments, ligand fragments and single-point mu-
tations. Powerful yet simple tools facilitate browsing, re-
trieval, querying, and inference of receptor overall and sub-
domain information. Several new or improved interactive
visualization options allow for online analysis and diagram
download. Collectively, this is in line with and could con-
tribute to the ongoing advances in receptor structure and
function, as well as structure-based drug design.
GPCRdb is the first to offer structure-based GPCR se-
quence alignments and generic residue numbers (24). As can
be seen from the three community-wide ‘GPCR Dock’ as-
sessments (42–44), there is a large interest and expertise in
GPCR homology modelling, and the increasing number of
structural templates have led to higher precision. GPCRdb
is currentlyworking towards providing built-inmodels of all
human receptors based on technologies that gave the best
receptor RMSD for the serotonin 5-HT1B receptor (44).
These involve the use of alternative templates for specific
substructures andGPCRposition-specific rotamer libraries
extracted from crystal structures.
GPCRdb allows for complementary data types to be as-
signed to receptor residue positions and visualized within
uniform residue diagrams and tables. This allows users to
integrate evolutionary conservation, pharmacological ef-
fects of single-point mutations and ligand interactions from
crystal structure complexes (45). Users have the option to
submit new mutation data to facilitate comparison with the
data in GPCRdb. Furthermore, GPCRdb is in the works of
a combined visualization of the above data types within one
simultaneous diagram.
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GPCRdb features a multi-residue site search that re-
trieves the profile of receptor targets that share the given
site, and by inference, also it’s associated function. This can
now be readily applied to analyses of structural motifs sta-
bilizing an (in)active receptor conformation, or ligand bind-
ing sites to assess ligand selectivity or polypharmacology. It
is expected that many more GPCR crystal structure com-
plexes will become available that provide further insights
into activation mechanisms, and the molecular sites of G
protein (13,14) and –arrestin (15) binding, and receptor
dimerisation (46–49). TheGPCRdb is ready to absorb these
data and aid the GPCR research community with their dis-
semination.
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